Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Income Before Tax

Profit after all operating and non-operating items but before income tax.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$88.61M, compared with -$64.05M a year earlier. Trailing-twelve-month income before tax was -$290.5M.

Context

  • Income before tax amounted to 513.2% of revenue in FY2025, up 209.5 pp from a year earlier.
  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$88.61M or moves back toward the trailing-twelve-month quarterly average of -$72.62M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$88.61M-37.1% QoQ
Last fiscal yearDec 2025
-$265.94M-37.4% YoY
LTMMar 2026
-$290.5M-50.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-38.3%——
1 year-37.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(265.94M) USD
Year-over-year change
-37.4%

Income Before Tax vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -50.7% is the 7th highest of 10, against a peer median of -13.5%.
  • Income before tax amounts to 558.2% of revenue for OCUL, versus a peer median of 818.3%.
OCUL Competitors
Income Before Tax for OCUL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HROWHarrow Health, Inc.LTM Mar 2026-$11.17M USD+48.2%—4.2%
STAASTAAR Surgical CompanyLTM Apr 2026-$19.56M USD+68.1%—6.7%
SGPSpyGlass Pharma, Inc. Common StockFY2025-$39.87M USD———
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$62.51M USD-395.9%—18764.2%
BLCOBausch + Lomb CorporationLTM Jun 2026-$65M USD+83.5%—1.2%
OCGNOcugen, Inc.LTM Mar 2026-$71.67M USD-24.7%—1605.2%
OCSOculis Holding AGLTM Mar 2026-CHF 95.35M CHF+7.5%—18919.2%
GKOSGlaukos CorporationLTM Jun 2026-$192.83M USD-109.2%—31.5%
KODKodiak Sciences Inc.LTM Sep 2026-$246.76M USD-13.5%——
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$271.37M USD-85.0%—3563.6%
OCULOcular Therapeutix, Inc.LTM Mar 2026-$290.5M USD-50.7%—558.2%
Peer median (excluding OCUL) —-13.5%—818.3%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.